Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | AKT1 | P31749 | 5/20 | 0.34 |
| ▸ | AKT2 | P31751 | 4/20 | 0.34 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.34 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.34 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25765554 | 0.94 | POLRMT (0.45) | POLRMTMAPK14 | |
| SCHEMBL25077274 | 0.91 | POLRMT (0.50) | POLRMTMAPK14AKT1AKT2AKT3 | |
| SCHEMBL25077089 | 0.91 | POLRMT (0.42) | POLRMTMAPK14AKT1AKT2AKT3 | |
| SCHEMBL26286057 | 0.91 | POLRMT (0.48) | POLRMTMAPK14AKT1AKT2AKT3 | |
| SCHEMBL25764487 | 0.89 | POLRMT (0.45) | POLRMTMAPK14AKT1AKT2AKT3 | |
| SCHEMBL26292858 | 0.89 | POLRMT (0.45) | POLRMTMAPK14AKT1AKT2AKT3 | |
| SCHEMBL25077245 | 0.89 | POLRMT (0.45) | POLRMTMAPK14AKT1AKT2AKT3 | |
| SCHEMBL25076981 | 0.87 | POLRMT (0.42) | POLRMTAKT1AKT2AKT3PIK3R1 | |
| SCHEMBL25077236 | 0.86 | POLRMT (0.45) | POLRMTLPAR1LPAR3 | |
| SCHEMBL25077051 | 0.86 | POLRMT (0.41) | POLRMTAKT1AKT2AKT3PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023023527-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PHOSPHO1, SGMS1, SGMS2 | POLRMT 266/4885MAPK14 3396/4885AKT1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.